Saverio Pancetti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Saverio Pancetti has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Palicelli
Pathology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy
3 shared publications - Francesca Sanguedolce
Department of Pathology, University of Foggia, 71122 Foggia, Italy
3 shared publications - Giovanni Martino
Pathology Unit, Azienda Ospedaliera Santa Maria di Terni, University of Perugia, 05100 Terni, Italy
3 shared publications - Giuseppe Broggi
Department of Medical and Surgical Sciences and Advanced Technologies “G.F. Ingrassia”, Anatomic Pathology, University of Catania, 95123 Catania, Italy
3 shared publications - Magda Zanelli
Pathology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy
3 shared publications - Maurizio Zizzo
Surgical Oncology Unit, Azienda Unità Sanitaria Locale—IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy
3 shared publications
Latest Publications
- 18 December 2025
- Published by Springer Nature in Endocrine Pathology
- Vol. 36 (1) , 52
Adult Pancreatoblastoma: A Challenge in the Differential Diagnosis of Pancreatic Neuroendocrine Neoplasms
- 18 December 2025
- Published by Springer Nature in Endocrine Pathology
- Vol. 36 (1) , 52
Adult Pancreatoblastoma: A Challenge in the Differential Diagnosis of Pancreatic Neuroendocrine Neoplasms
- Open Access
- 23 April 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (9) , 2913
Poroelastic Characterization of Human Vertebral Metastases to Inform a Transdisciplinary Assessment of Spinal Tumors
Background and Objectives: Vertebral metastases often lead to pathological fractures and spinal cord compression, thus impacting patient quality of life. This study aimed to quantify the poroelastic mechanical properties of vertebral metastatic tissue explanted during spine surgery and correlate it with clinical data. Methods: Nine patients (61.7 ± 13.1 years) were prospectively recruited from April 2021 to February 2022, where 78% had a vertebral fracture. Demographic and metastases data, including primary origin, spinal level, lesion volume, and SINS score, were collected, and tissue specimens were explanted during surgery. Using a newly developed portable experimental setup, confined compression creep tests were conducted to measure the aggregate modulus and permeability of each sample. Dealing with limited samples, the results were expressed as the median (min; max). Results: Specimens from the unfractured vertebrae had higher aggregate modulus (200.35 (149.80; 250.90) kPa vs. 14.47 (8.27; 35.89) kPa) and higher permeability (0.02 (0.01; 0.03) mm4/N·s vs. 0.41 (0.10; 4.68) mm4/N·s) compared with the specimens from the fractured vertebrae. Histology revealed prominent levels of neoplastic cell infiltration and disruption of typical bone matrix architecture. Specimens with low neoplastic cellularity had comparable or slightly higher poroelastic properties compared to high cellularity. No clear trend was observed between the mechanical properties and SINS score, nor between the mechanical properties, percentage lesion volume, and fractures. Conclusions: Despite the limited sample size, the poroelastic characterization revealed relevant insights to investigate in future research. A transdisciplinary assessment of vertebral metastases, incorporating poroelastic testing, deserves further attention and could enhance the treatment options.
- 23 April 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (9) , 2913
Open AccessPoroelastic Characterization of Human Vertebral Metastases to Inform a Transdisciplinary Assessment of Spinal Tumors
Background and Objectives: Vertebral metastases often lead to pathological fractures and spinal cord compression, thus impacting patient quality of life. This study aimed to quantify the poroelastic mechanical properties of vertebral metastatic tissue explanted during spine surgery and correlate it with clinical data. Methods: Nine patients (61.7 ± 13.1 years) were prospectively recruited from April 2021 to February 2022, where 78% had a vertebral fracture. Demographic and metastases data, including primary origin, spinal level, lesion volume, and SINS score, were collected, and tissue specimens were explanted during surgery. Using a newly developed portable experimental setup, confined compression creep tests were conducted to measure the aggregate modulus and permeability of each sample. Dealing with limited samples, the results were expressed as the median (min; max). Results: Specimens from the unfractured vertebrae had higher aggregate modulus (200.35 (149.80; 250.90) kPa vs. 14.47 (8.27; 35.89) kPa) and higher permeability (0.02 (0.01; 0.03) mm4/N·s vs. 0.41 (0.10; 4.68) mm4/N·s) compared with the specimens from the fractured vertebrae. Histology revealed prominent levels of neoplastic cell infiltration and disruption of typical bone matrix architecture. Specimens with low neoplastic cellularity had comparable or slightly higher poroelastic properties compared to high cellularity. No clear trend was observed between the mechanical properties and SINS score, nor between the mechanical properties, percentage lesion volume, and fractures. Conclusions: Despite the limited sample size, the poroelastic characterization revealed relevant insights to investigate in future research. A transdisciplinary assessment of vertebral metastases, incorporating poroelastic testing, deserves further attention and could enhance the treatment options.
- 2 April 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 27 (11) , 3029-3039
AI differentiates radionecrosis from true progression in brain metastasis upon stereotactic radiosurgery: Analysis of 124 histologically assessed lesions
Background: Differentiating radionecrosis from neoplastic progression after stereotactic radiosurgery (SRS) for brain metastases is a diagnostic challenge. Previous studies have often been limited by datasets lacking histologically confirmed diagnoses. This study aimed to develop automated models for distinguishing radionecrosis from disease progression on brain MRI, utilizing cases with definitive histopathological confirmation. Methods: This multi-center retrospective study included patients who underwent surgical resection for suspected brain metastasis progression after SRS. Presurgical FLAIR and postcontrast T1 (T1w-ce) were segmented using a convolutional neural network (CNN) and compared with manual segmentation by means of Dice score. Radiomics features were extracted from each lesion, and a Random Forest model was trained on 70% of the internal dataset and evaluated on the remaining 30% and the complete external dataset. A 3DResNet-CNN was trained on the same split dataset. Validation was performed on the external dataset. Postsurgical histology was available for all cases. Results: One hundred and twenty four brain metastases were included (104 from center 1 and 20 from center 2). Sole radionecrosis was histologically detected in 34 cases (27.4%). In the internal dataset, univariate and multivariate analysis identified 131 significantly different radiomics features, including GLDM_DNUN and GLDM_SDE within the enhancing area on the T1w-ce. On the external test dataset, the Random Forest model and the 3DResNet-CNN yielded accurate results in terms of accuracy (80.0%, 85.0%), AUROC (0.830, 0.893) and sensitivity (92.8%, 100%) in radionecrosis prediction, respectively. Conclusion: Artificial intelligence could be employed to differentiate between radionecrosis and brain metastasis progression upon SRS, potentially reducing unnecessary surgical interventions.
- 2 April 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 27 (11) , 3029-3039
AI differentiates radionecrosis from true progression in brain metastasis upon stereotactic radiosurgery: Analysis of 124 histologically assessed lesions
Background: Differentiating radionecrosis from neoplastic progression after stereotactic radiosurgery (SRS) for brain metastases is a diagnostic challenge. Previous studies have often been limited by datasets lacking histologically confirmed diagnoses. This study aimed to develop automated models for distinguishing radionecrosis from disease progression on brain MRI, utilizing cases with definitive histopathological confirmation. Methods: This multi-center retrospective study included patients who underwent surgical resection for suspected brain metastasis progression after SRS. Presurgical FLAIR and postcontrast T1 (T1w-ce) were segmented using a convolutional neural network (CNN) and compared with manual segmentation by means of Dice score. Radiomics features were extracted from each lesion, and a Random Forest model was trained on 70% of the internal dataset and evaluated on the remaining 30% and the complete external dataset. A 3DResNet-CNN was trained on the same split dataset. Validation was performed on the external dataset. Postsurgical histology was available for all cases. Results: One hundred and twenty four brain metastases were included (104 from center 1 and 20 from center 2). Sole radionecrosis was histologically detected in 34 cases (27.4%). In the internal dataset, univariate and multivariate analysis identified 131 significantly different radiomics features, including GLDM_DNUN and GLDM_SDE within the enhancing area on the T1w-ce. On the external test dataset, the Random Forest model and the 3DResNet-CNN yielded accurate results in terms of accuracy (80.0%, 85.0%), AUROC (0.830, 0.893) and sensitivity (92.8%, 100%) in radionecrosis prediction, respectively. Conclusion: Artificial intelligence could be employed to differentiate between radionecrosis and brain metastasis progression upon SRS, potentially reducing unnecessary surgical interventions.
- Open Access
- 29 April 2023
- Published by Mattioli1885 in Dermatology Practical & Conceptual
- Vol. 13 (2) , e2023130
Sorafenib-Induced Acute Generalized Exanthematous Pustulosis
Citation: Cortese A, Pancetti S, Pressiani T, et al. Sorafenib-Induced Acute Generalized Exanthematous Pustulosis. Dermatol Pract Concept. 2023;13(2):e2023130. DOI: https://doi.org/10.5826/dpc.1302a130 Accepted: November 17, 2022; Published: April 2023 Copyright: ©2023 Cortese et al. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (BY-NC-4.0), https://creativecommons.org/licenses/by-nc/4.0/, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original authors and source are credited. Funding: None. Competing interests: None. Authorship: All authors have contributed significantly to this publication. Corresponding author: Andrea Cortese, MD, Dermatology, Humanitas Research Hospital – IRCCS, Via A. Manzoni 56, 20089 Rozzano (MI), Italy. E-mail: andreacortese08@gmail.com Keywords : sorafenib, acute generalized exanthematous pustulosis, severe cutaneous adverse reaction, tyrosin-kinase inhibitors This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
- 29 April 2023
- Published by Mattioli1885 in Dermatology Practical & Conceptual
- Vol. 13 (2) , e2023130
Open AccessSorafenib-Induced Acute Generalized Exanthematous Pustulosis
Citation: Cortese A, Pancetti S, Pressiani T, et al. Sorafenib-Induced Acute Generalized Exanthematous Pustulosis. Dermatol Pract Concept. 2023;13(2):e2023130. DOI: https://doi.org/10.5826/dpc.1302a130 Accepted: November 17, 2022; Published: April 2023 Copyright: ©2023 Cortese et al. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (BY-NC-4.0), https://creativecommons.org/licenses/by-nc/4.0/, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original authors and source are credited. Funding: None. Competing interests: None. Authorship: All authors have contributed significantly to this publication. Corresponding author: Andrea Cortese, MD, Dermatology, Humanitas Research Hospital – IRCCS, Via A. Manzoni 56, 20089 Rozzano (MI), Italy. E-mail: andreacortese08@gmail.com Keywords : sorafenib, acute generalized exanthematous pustulosis, severe cutaneous adverse reaction, tyrosin-kinase inhibitors This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
- Open Access
Mast Cell Leukemia: An Update with a Practical Review
Mast cell leukemia (MCL) is the leukemic form of SM with at least 20% mostly immature mast cells on bone marrow aspirate. MCL may develop de novo, in the absence of a prior SM, or it may represent a progression from a previous SM. MCL may be sub-divided into the more frequent, aggressive acute form with signs of organ damage (C-findings) and the chronic form lacking C-findings and presenting a more stable course, although over time, progression to acute MCL is common. The 2022 WHO subtype of MCL with an associated hematological neoplasm was renamed MCL with an associated myeloid neoplasm in the 2022 International Consensus Classification (ICC). The relevance of the distinction between the leukemic and aleukemic forms based on the percentage of circulating mast cells is a matter of debate. The current knowledge on MCL is restricted mainly to single reports or case series with a limited number of larger studies. Our aim is to provide a comprehensive overview of this rare disease in terms of clinical manifestations, morphology, phenotype, molecular characteristics, differential diagnosis, outcome and treatment. A general overview on mastocytosis is also included.
Open AccessMast Cell Leukemia: An Update with a Practical Review
Mast cell leukemia (MCL) is the leukemic form of SM with at least 20% mostly immature mast cells on bone marrow aspirate. MCL may develop de novo, in the absence of a prior SM, or it may represent a progression from a previous SM. MCL may be sub-divided into the more frequent, aggressive acute form with signs of organ damage (C-findings) and the chronic form lacking C-findings and presenting a more stable course, although over time, progression to acute MCL is common. The 2022 WHO subtype of MCL with an associated hematological neoplasm was renamed MCL with an associated myeloid neoplasm in the 2022 International Consensus Classification (ICC). The relevance of the distinction between the leukemic and aleukemic forms based on the percentage of circulating mast cells is a matter of debate. The current knowledge on MCL is restricted mainly to single reports or case series with a limited number of larger studies. Our aim is to provide a comprehensive overview of this rare disease in terms of clinical manifestations, morphology, phenotype, molecular characteristics, differential diagnosis, outcome and treatment. A general overview on mastocytosis is also included.
- Open Access
Primary Large B-Cell Lymphoma of Immune-Privileged Sites of the Cerebellum: A Case Series and Review of the Literature
Primary large B-cell lymphoma of immune-privileged sites (IP-LBCL) is a rare malignant hematological neoplasm. Involvement of the cerebellum is even rarer and its diagnosis is often difficult to make due to its non-specific clinical and radiological presentation. Methods: We reported 3 cases of cerebellar IP-LBCL followed at our hospital and reviewed the medical literature to unravel the peculiarities of this poorly studied entity. Outcomes: Analyzing our cases and reviewing the literature, we could collect and study 26 cases of cerebellar IP-LBCL. To the best of our knowledge, this is the largest cohort of such patients currently published. Conclusion: Cerebellar IP-LBCL presents more often in adult females with cerebellum-related focal neurological signs such as ataxia, headache, and nausea. Histological confirmation is mandatory for a correct diagnosis and treatment and all cases feature diffuse large B-cell lymphoma histopathology. Compared to other encephalic IP-LBCL, cerebellar cases seem to include a higher number of cases with germinal center B-cell phenotype and better survival. These differences may be related to a different immune microenvironment and especially immunoregulation that distinguishes the cerebellum from other areas of the CNS.
Open AccessPrimary Large B-Cell Lymphoma of Immune-Privileged Sites of the Cerebellum: A Case Series and Review of the Literature
Primary large B-cell lymphoma of immune-privileged sites (IP-LBCL) is a rare malignant hematological neoplasm. Involvement of the cerebellum is even rarer and its diagnosis is often difficult to make due to its non-specific clinical and radiological presentation. Methods: We reported 3 cases of cerebellar IP-LBCL followed at our hospital and reviewed the medical literature to unravel the peculiarities of this poorly studied entity. Outcomes: Analyzing our cases and reviewing the literature, we could collect and study 26 cases of cerebellar IP-LBCL. To the best of our knowledge, this is the largest cohort of such patients currently published. Conclusion: Cerebellar IP-LBCL presents more often in adult females with cerebellum-related focal neurological signs such as ataxia, headache, and nausea. Histological confirmation is mandatory for a correct diagnosis and treatment and all cases feature diffuse large B-cell lymphoma histopathology. Compared to other encephalic IP-LBCL, cerebellar cases seem to include a higher number of cases with germinal center B-cell phenotype and better survival. These differences may be related to a different immune microenvironment and especially immunoregulation that distinguishes the cerebellum from other areas of the CNS.
- Open Access
- 6 January 2023
- Published by MDPI AG in Current Oncology
- Vol. 30 (1) , 824-831
CD5-Negative Primary Mantle Cell Lymphoma Presenting with a Bilateral Conjunctival Mass: A Potential Diagnostic Pitfall
Mantle cell lymphoma is a B-cell malignancy, which, in its classic form, usually involves lymph nodes and extranodal sites, and, among the extranodal sites, the gastrointestinal tract and the Waldeyer’s ring are most prevalent. MCL is rarely reported in the ocular adnexa, a site more frequently affected by extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue, which is a form of low-grade malignancy. The diagnosis of MCL presenting in the ocular adnexa requires special attention as its rarity in this location combined with the not uncommon CD5 negativity of the disease when occurring in the ocular adnexa, may lead the pathologist to overlook the diagnosis and misinterpret MCL as marginal zone B cell lymphoma, which has a totally different behavior. Herein, we present a case of primary bilateral conjunctival CD5-negative MCL in a patient having no other sites affected by lymphoma and we discuss possible diagnostic pitfalls.
- 6 January 2023
- Published by MDPI AG in Current Oncology
- Vol. 30 (1) , 824-831
Open AccessCD5-Negative Primary Mantle Cell Lymphoma Presenting with a Bilateral Conjunctival Mass: A Potential Diagnostic Pitfall
Mantle cell lymphoma is a B-cell malignancy, which, in its classic form, usually involves lymph nodes and extranodal sites, and, among the extranodal sites, the gastrointestinal tract and the Waldeyer’s ring are most prevalent. MCL is rarely reported in the ocular adnexa, a site more frequently affected by extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue, which is a form of low-grade malignancy. The diagnosis of MCL presenting in the ocular adnexa requires special attention as its rarity in this location combined with the not uncommon CD5 negativity of the disease when occurring in the ocular adnexa, may lead the pathologist to overlook the diagnosis and misinterpret MCL as marginal zone B cell lymphoma, which has a totally different behavior. Herein, we present a case of primary bilateral conjunctival CD5-negative MCL in a patient having no other sites affected by lymphoma and we discuss possible diagnostic pitfalls.
- Open Access
Intravascular NK/T-Cell Lymphoma: What We Know about This Diagnostically Challenging, Aggressive Disease
Intravascular lymphoma is a form of lymphoid malignancy characterized by neoplastic cells growing almost exclusively within the lumina of small- to medium-sized blood vessels. Most cases are of B-cell origin with rare cases of natural killer or T-cell lineage. Extranodal sites are affected, mainly the skin and central nervous system, although any organ may be involved. Intravascular NK/T-cell lymphoma deserves special attention because of its clinicopathologic features and the need for adequate immunophenotyping combined with clonality test for a proper diagnosis. Moreover, intravascular NK/T-cell lymphoma is strongly linked to Epstein–Barr virus (EBV), which is considered to play a role in tumorigenesis and to be responsible for the aggressive behavior of the disease. In this paper, we review the current knowledge on this rare lymphoma and, in particular, the most recent advances about its molecular landscape. The main distinguishing features with other EBV-related entities, such as extranodal NK/T-cell lymphoma, EBV-positive primary nodal T/NK-cell lymphoma, and aggressive NK-cell leukemia, are discussed to help pathologists obtain the correct diagnosis and consequently develop an adequate and prompt therapy response.
Open AccessIntravascular NK/T-Cell Lymphoma: What We Know about This Diagnostically Challenging, Aggressive Disease
Intravascular lymphoma is a form of lymphoid malignancy characterized by neoplastic cells growing almost exclusively within the lumina of small- to medium-sized blood vessels. Most cases are of B-cell origin with rare cases of natural killer or T-cell lineage. Extranodal sites are affected, mainly the skin and central nervous system, although any organ may be involved. Intravascular NK/T-cell lymphoma deserves special attention because of its clinicopathologic features and the need for adequate immunophenotyping combined with clonality test for a proper diagnosis. Moreover, intravascular NK/T-cell lymphoma is strongly linked to Epstein–Barr virus (EBV), which is considered to play a role in tumorigenesis and to be responsible for the aggressive behavior of the disease. In this paper, we review the current knowledge on this rare lymphoma and, in particular, the most recent advances about its molecular landscape. The main distinguishing features with other EBV-related entities, such as extranodal NK/T-cell lymphoma, EBV-positive primary nodal T/NK-cell lymphoma, and aggressive NK-cell leukemia, are discussed to help pathologists obtain the correct diagnosis and consequently develop an adequate and prompt therapy response.